Vigene Biosciences
Rockville
About Vigene Biosciences
Vigene develops gene delivery technologies with the mission to advance biomedical research and to make gene therapy affordable. It offers both research-grade and cGMP-grade AAV, lentivirus, and adenovirus-based products and custom services. Some of its product offerings include ready-to-ship genome-wide human cDNA ORFs on adenoviral or lentiviral vectors, AAV shRNA constructs, pre-made control GFP viruses, AAV biosensors developed in partnership with Janelia Research Campus, AAV alpha-synuclein vectors developed in partnership with The Michael J Fox Foundation, and many others. Vigene was founded in 2012 by senior scientists with expertise in the fields of virology and gene therapy. It is headquartered at Rockville, Maryland.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $10.5M
- Funding stage: M&A
- Last round: Series Unknown (Mar 2020)
- Website: vigenebio.com
- Phone: +1-301-251-6638
Industries & Categories
Biotechnology, Genetics, Medical
Social Profiles
Canonical: https://fsome.com/organization/vigene-biosciences-100914 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.